GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

“GeneDx is at the forefront of genomic discovery, accelerating gene-disease insights, advancing long-read sequencing, and improving access so more families can reach answers sooner,” said Britt Johnson, PhD, FACMG, SVP of Medical Affairs at GeneDx. “Powered by the scale and diversity of GeneDx Infinity and the deep expertise of our team, we are pioneering innovations that elevate diagnostic accuracy, deepen scientific understanding, and bring the full potential of precision medicine to patients and families around the world.”

At NSGC, GeneDx will showcase innovation and clinical breakthroughs powered by GeneDx Infinity, the largest rare disease dataset. The company will highlight Infinity’s role in identifying novel gene-disease discoveries, which enable GeneDx to offer clear answers for clinicians and earlier, more accurate diagnoses for patients and families. Additionally, GeneDx is showcasing how data generated from genomic testing drives progress and impact across the healthcare ecosystem, from patients and advocacy groups to clinical laboratories to biopharma companies and beyond. GeneDx will also highlight data supporting the potential of long read sequencing and work being done on reimbursement and access.

GeneDx’s presence at NSGC underscores the company’s commitment to advancing precision medicine through innovation, scale and real-world evidence, while empowering genetic counselors with tools and insights that transform patient care. With 1000+ scientific publications and counting, GeneDx is generating crucial data that demonstrate that exome and genome testing is the standard of care. The GeneDx team is exhibiting at booth #600, educating genetic counselors about the leading GeneDx ExomeDx and GenomeDx tests, as well as the scientific presentations listed below.

Shaping equitable access and reimbursement
Let’s make a deal: Working together to navigate coverage, billing and coding whammies – Friday, November 7, 2-3:15pm, Ballroom 6ABC

Sarah Soto, MC, CGC, Head of Payor Evidence Strategy at GeneDx, will join industry payer and clinical policy experts to discuss the evolving reimbursement landscape for genetic testing and opportunities for genetic counselors to help shape more equitable access. This session will provide practical policy insight for the genetic counselor community.